View the new WinRho® eDetail

View the eDetail to learn more about a front-line2 therapy for ITP.

Administration of WinRho® SDF

Administration of WinRho® SDF is convenient, requiring an intravenous infusion over three to five minutes.


Tolerability1

In clinical trials of subjects with childhood acute ITP, adults and children with chronic
ITP, and adults and children with ITP secondary to HIV, only 7% of infusions were
associated with at least one adverse event related to WinRho® SDF.

WinRho® SDF Tolerability*
Most Common Adverse Events
Frequency †
Headache
2%
Chills
<2%
Fever
1%

† n=848 infusions
*Studies were performed using WinRho®/WinRho® SD

WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similiar elimination half-lives. WinRho®  SDF must be administered via the intravenous route for the treatment of ITP.

Please see Important Safety Information and Prescribing Information.

  1. WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation, Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
  2. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005; 106: 2244-2251.